Standard BioTools (LAB) Debt/Equity Ratio: History & Chart

Standard BioTools Inc.(LAB)

Medical - Specialties · Boston, MA

$0.78+0.02 (+2.36%)

Delayed quote: Oct 6, 2026, 10:24 AM EDT

About Standard BioTools Inc.

Standard BioTools Inc., together with its subsidiaries, develops, manufactures, and sells a range of instrumentation, consumables, and services to scientists and biomedical researchers to develop therapeutics in the Americas, Europe, the Middle East, Africa, and the Asia pacific. The company operates through Proteomics and Genomics segments. Its proteomics and genomics include instruments, consumables, and assays for clinical and diagnostic uses. The company also provides SomaScan platform that enables researchers to measure proteins simultaneously and provides deep insights into biological processes and disease mechanisms; CyTOF technology platform that uses metal-tagged antibodies and time-of-flight mass spectrometry to eliminate signal interference and expand multiplexing capabilities; Hyperion, a spatial biology platform, which unlocks deeper insights into tissue organization by preserving spatial context while enabling high-dimensional molecular and proteomic analysis; and Biomark X9 system that redefines high-throughput genomics for quantitative polymerase chain reaction applications. The company sells its instruments and consumables for research use only to academic research institutions, translational research and medicine centers, cancer centers, and clinical research laboratories, as well as biopharmaceutical, biotechnology, and plant and animal research companies. It has license agreements with California Institute of Technology, Harvard University, and Caliper Life Sciences, Inc. The company was formerly known as Fluidigm Corporation and changed its name to Standard BioTools Inc. in November 2001. Standard BioTools Inc. was incorporated in 1999 and is headquartered in Boston, Massachusetts.

Boston, MA

387 employees

www.standardbio.com

Healthcare / Medical - Specialties

Sector: Healthcare
Industry: Medical - Specialties
CEO: Michael Egholm

View full financials

LAB Debt to Equity Ratio Metrics

DEBT TO EQUITY RATIO

0.05

DEBT TO EQUITY RATIO AVG TTM

0.06

DEBT TO EQUITY RATIO AVG 3Y

0.10

DEBT TO EQUITY RATIO AVG 5Y

-0.05

DEBT TO EQUITY RATIO AVG 10Y

0.83

DEBT TO EQUITY RATIO AVG 15Y

0.55

DEBT TO EQUITY RATIO AVG 20Y

0.42

CURRENT VS TTM AVG

-16.95%

CURRENT VS 3Y AVG

-46.48%

CURRENT VS 5Y AVG

+207.96%

CURRENT VS 10Y AVG

-93.72%

CURRENT VS 15Y AVG

-90.59%

CURRENT VS 20Y AVG

-87.76%

SECTOR MEDIAN · HEALTHCARE

0.13

median of 528 covered companies

CURRENT VS SECTOR MEDIAN

-59.99%

vs the sector median at left

NAME	MARKET CAP	DEBT TO EQUITY RATIO	TTM	3Y	5Y
Standard BioTools Inc. (LAB)	$305.73M	0.05	0.06	0.10	-0.05
Mobia Medical, Inc. Common Stock (MOBI)vs ›	$308.22M	0.05	N/A	N/A	N/A
Benitec Biopharma Inc. (BNTC)vs ›	$297.18M	0.00	0.01	0.70	0.51
CapsoVision, Inc. (CV)vs ›	$319.77M	0.05	0.07	0.07	0.07
Cabaletta Bio, Inc. (CABA)vs ›	$321.22M	0.12	0.17	0.10	0.07
C4 Therapeutics, Inc. (CCCC)vs ›	$322.30M	0.23	0.27	0.28	0.22
Larimar Therapeutics, Inc. (LRMR)vs ›	$286.20M	0.04	0.04	0.05	0.06
BridgeBio Oncology Therapeutics Inc. (BBOT)vs ›	$284.38M	0.01	0.01	0.01	0.01
Abeona Therapeutics Inc. (ABEO)vs ›	$282.98M	0.16	0.34	0.33	0.27
Fulcrum Therapeutics, Inc. (FULC)vs ›	$281.92M	0.02	0.03	0.04	0.03

NAME

MARKET CAP

DEBT TO EQUITY RATIO

TTM

Standard BioTools Inc. (LAB)

$305.73M

0.05

0.06

0.10

-0.05

Mobia Medical, Inc. Common Stock (MOBI)vs ›

$308.22M

0.05

N/A

Benitec Biopharma Inc. (BNTC)vs ›

$297.18M

0.00

0.01

0.70

0.51

CapsoVision, Inc. (CV)vs ›

$319.77M

0.05

0.07

Cabaletta Bio, Inc. (CABA)vs ›

$321.22M

0.12

0.17

0.10

0.07

C4 Therapeutics, Inc. (CCCC)vs ›

$322.30M

0.23

0.27

0.28

0.22

Larimar Therapeutics, Inc. (LRMR)vs ›

$286.20M

0.04

0.05

0.06

BridgeBio Oncology Therapeutics Inc. (BBOT)vs ›

$284.38M

0.01

Abeona Therapeutics Inc. (ABEO)vs ›

$282.98M

0.16

0.34

0.33

0.27

Fulcrum Therapeutics, Inc. (FULC)vs ›

$281.92M

0.02

0.03

0.04

0.03

Debt to Equity Ratio FAQ

What is the debt to equity ratio for Standard BioTools Inc. (LAB)?

The debt to equity ratio for LAB stock is 0.05.

Is Standard BioTools Inc.'s debt to equity ratio high or low?

The debt to equity ratio of 0.05 is 208% above its 5-year average of -0.05, around the middle of its 5-year range (-2.77–6.33).

What is the TTM average debt to equity ratio for Standard BioTools Inc. (LAB)?

The TTM average debt to equity ratio for LAB stock is 0.06.

What is the 3Y average debt to equity ratio for Standard BioTools Inc. (LAB)?

The 3Y average debt to equity ratio for LAB stock is 0.10.

What is the 5Y average debt to equity ratio for Standard BioTools Inc. (LAB)?

The 5Y average debt to equity ratio for LAB stock is -0.05.

What is the 10Y average debt to equity ratio for Standard BioTools Inc. (LAB)?

The 10Y average debt to equity ratio for LAB stock is 0.83.

What is the 15Y average debt to equity ratio for Standard BioTools Inc. (LAB)?

The 15Y average debt to equity ratio for LAB stock is 0.55.

What is the 20Y average debt to equity ratio for Standard BioTools Inc. (LAB)?

The 20Y average debt to equity ratio for LAB stock is 0.42.

DATE	DEBT TO EQUITY RATIO
2026-06-30	0.05
2026-03-31	0.05
2025-12-31	0.07
2025-09-30	0.07
2025-06-30	0.07
2025-03-31	0.07
2024-12-31	0.07
2024-09-30	0.18
2024-06-30	0.18
2024-03-31	0.16
2023-12-31	0.60
2023-09-30	-0.76
2023-06-30	-0.89
2023-03-31	-1.05
2022-12-31	-1.26
2022-09-30	-1.64
2022-06-30	-2.77
2022-03-31	6.33
2021-12-31	1.18
2021-09-30	1.06
2021-06-30	0.88
2021-03-31	0.77
2020-12-31	0.69
2020-09-30	0.63
2020-06-30	0.72
2020-03-31	0.67
2019-12-31	0.39
2019-09-30	0.35
2019-06-30	0.34
2019-03-31	0.32
2018-12-31	2.39
2018-09-30	7.56
2018-06-30	4.79
2018-03-31	3.38
2017-12-31	6.31
2017-09-30	5.00
2017-06-30	8.15
2017-03-31	5.07
2016-12-31	3.66
2016-09-30	2.87
2016-06-30	2.31
2016-03-31	1.97
2015-12-31	1.70
2015-09-30	1.58
2015-06-30	1.47
2015-03-31	1.37
2014-12-31	1.30
2014-09-30	1.26
2014-06-30	1.21
2014-03-31	1.17
2013-12-31	0.00
2013-09-30	0.00
2013-06-30	0.00
2013-03-31	0.00
2012-12-31	0.00
2012-09-30	0.02
2012-06-30	0.10
2012-03-31	0.12
2011-12-31	0.18
2011-09-30	0.20
2011-06-30	0.21
2011-03-31	0.21
2010-12-31	-0.09
2010-09-30	-10.08
2010-06-30	0.00
2010-03-31	0.00
2009-12-31	-0.08
2008-12-31	-0.10
2008-06-30	-0.11
2007-12-31	-0.11

DATE

DEBT TO EQUITY RATIO

2026-06-30

0.05

2026-03-31

0.05

2025-12-31

0.07

2025-09-30

0.07

2025-06-30

0.07

2025-03-31

0.07

2024-12-31

0.07

2024-09-30

0.18

2024-06-30

0.18

2024-03-31

0.16

2023-12-31

0.60

2023-09-30

-0.76

2023-06-30

-0.89

2023-03-31

-1.05

2022-12-31

-1.26

2022-09-30

-1.64

2022-06-30

-2.77

2022-03-31

6.33

2021-12-31

1.18

2021-09-30

1.06

2021-06-30

0.88

2021-03-31

0.77

2020-12-31

0.69

2020-09-30

0.63

2020-06-30

0.72

2020-03-31

0.67

2019-12-31

0.39

2019-09-30

0.35

2019-06-30

0.34

2019-03-31

0.32

2018-12-31

2.39

2018-09-30

7.56

2018-06-30

4.79

2018-03-31

3.38

2017-12-31

6.31

2017-09-30

5.00

2017-06-30

8.15

2017-03-31

5.07

2016-12-31

3.66

2016-09-30

2.87

2016-06-30

2.31

2016-03-31

1.97

2015-12-31

1.70

2015-09-30

1.58

2015-06-30

1.47

2015-03-31

1.37

2014-12-31

1.30

2014-09-30

1.26

2014-06-30

1.21

2014-03-31

1.17

2013-12-31

0.00

2013-09-30

0.00

2013-06-30

0.00

2013-03-31

0.00

2012-12-31

0.00

2012-09-30

0.02

2012-06-30

0.10

2012-03-31

0.12

2011-12-31

0.18

2011-09-30

0.20

2011-06-30

0.21

2011-03-31

0.21

2010-12-31

-0.09

2010-09-30

-10.08

2010-06-30

0.00

2010-03-31

0.00

2009-12-31

-0.08

2008-12-31

-0.10

2008-06-30

-0.11

2007-12-31

-0.11

Debt to Equity Ratio: 0.05

LAB Debt to Equity Ratio

LAB Average Debt to Equity Ratio Chart

LAB Current vs Average Debt to Equity Ratio Chart

LAB Debt to Equity Ratio Metrics

LAB Competitors' Debt to Equity Ratio

Financial Health

Debt to Equity Ratio Formula & Definition

Debt to Equity Ratio FAQ

LAB Debt to Equity Ratio History

Related Metrics